you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes
New generics plus bladder cancer concerns mean you'll hear MORE controversy about using pioglitazone (Actos) for type 2 diabetes.
Actos is one of the top 25 prescribed drugs in the U.S...and lower prices for the generic could tempt more prescribers to use it.
But some clinicians are reluctant to use it due to growing concerns about bladder cancer.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote